Streetbeat News

Products Services

RXRX

Recursion Pharmaceuticals has announced the Phase 2 SYCAMORE trial of REC-994, focusing on safety and tolerability in treating symptomatic cerebral cavernous malformation. This development is crucial for the company's pipeline and future growth.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 12:04 pm

BIVI

BioVie has received FDA authorization for an investigational new drug application to conduct a Phase 2 trial of Bezisterim for Long COVID. This authorization enables the company to receive an additional $12.6 million grant from the US Department of Defense and proceed with the trial.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 12:01 pm

IGC

IGC Pharma (AMEX:IGC) has received mixed analyst ratings, with a recent increase in bullish sentiment. Analysts have set a 12-month price target range of $3.25 to $3.75, reflecting a 5.11% increase from previous targets. Despite financial challenges, such as a -50.99% revenue decline, IGC Pharma maintains a strong market position with promising drug assets.

Portfolio Pulse from Benzinga Insights

September 03, 2024 | 12:00 pm

LUCD

PAVM

Lucid Diagnostics Inc. has partnered with Front Line Mobile Health to enhance esophageal cancer screening among first responders, particularly firefighters, through co-marketing initiatives. This collaboration aims to promote Lucid's EsoGuard® Esophageal DNA test for early detection of esophageal precancer.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 11:57 am

SNY

Sanofi's investigational drug tolebrutinib showed mixed results in phase 3 trials for multiple sclerosis. While it met the primary endpoint in the HERCULES study for non-relapsing secondary progressive multiple sclerosis, it failed in the GEMINI studies for relapsing forms. Despite concerns over liver safety and effectiveness, analysts see a potential $1-2 billion opportunity.

Portfolio Pulse from Vandana Singh

September 03, 2024 | 11:56 am

ARWR

Arrowhead Pharmaceuticals shares rose following positive results from the Phase 3 PALISADE study of plozasiran for familial chylomicronemia syndrome.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 11:56 am

MTEK

Maris-Tech has been granted a U.S. patent for a new forward error correction optimization method that reduces overhead data in media streaming. This innovation could enhance the efficiency of media communication.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 11:52 am

PSNY

Polestar Automotive (NASDAQ:PSNY) has appointed Jean-Francois Mady, a former Stellantis executive, as its new CFO, effective October 21. This follows the recent appointment of Michael Lohscheller as CEO. Polestar, controlled by Geely, reported an 80% increase in car deliveries in Q2 and aims for further sales growth with the upcoming production of Polestar 3 in South Carolina.

Portfolio Pulse from Anan Ashraf

September 03, 2024 | 11:51 am

PCVX

Vaxcyte shares rise as the company advances VAX-31 to a Phase 3 program after positive Phase 1/2 results.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 11:46 am

DYN

Dyne Therapeutics shares are trading lower following the announcement of new clinical data from its Phase 1/2 DELIVER trial of DYNE-251. The trial showed unprecedented dystrophin expression and functional improvement in patients with Duchenne muscular dystrophy amenable to exon 51 skipping.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 11:44 am